Tags

Type your tag names separated by a space and hit enter

Evaluation of the clinical use of tepoxalin and meloxicam in cats.
J Feline Med Surg. 2013 Aug; 15(8):678-90.JF

Abstract

Medical records where tepoxalin (Zubrin) or meloxicam (Metacam) were prescribed in cats were reviewed and data extracted. Comparisons were performed for exploring changes between pre- and post-non-steroidal anti-inflammatory drug course laboratory tests. Seventy-nine medical records fit the inclusion criteria (n = 57 and n = 22, tepoxalin and meloxicam, respectively). The median dosages administered were 13 and 0.029 mg/kg(/)day (tepoxalin and meloxicam, respectively). Median prescription durations were 11 (2-919) and 93 (4-1814) days for tepoxalin and meloxicam, respectively. Suspected adverse events were reported for tepoxalin (9%, 5/57 cats) and meloxicam (18%, 4/22 cats) a median of 774 and 448 days, respectively, after the prescription started. For cats prescribed meloxicam, there were several statistically significant changes for serum biochemistry and hematology parameters, but median values were within normal limits. These valuable clinical data suggest that tepoxalin and meloxicam are well tolerated in the clinical setting at the doses prescribed in this study.

Authors+Show Affiliations

Comparative Pain Research Laboratory, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23349526

Citation

Charlton, Anna N., et al. "Evaluation of the Clinical Use of Tepoxalin and Meloxicam in Cats." Journal of Feline Medicine and Surgery, vol. 15, no. 8, 2013, pp. 678-90.
Charlton AN, Benito J, Simpson W, et al. Evaluation of the clinical use of tepoxalin and meloxicam in cats. J Feline Med Surg. 2013;15(8):678-90.
Charlton, A. N., Benito, J., Simpson, W., Freire, M., & Lascelles, B. D. (2013). Evaluation of the clinical use of tepoxalin and meloxicam in cats. Journal of Feline Medicine and Surgery, 15(8), 678-90. https://doi.org/10.1177/1098612X12473994
Charlton AN, et al. Evaluation of the Clinical Use of Tepoxalin and Meloxicam in Cats. J Feline Med Surg. 2013;15(8):678-90. PubMed PMID: 23349526.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of the clinical use of tepoxalin and meloxicam in cats. AU - Charlton,Anna N, AU - Benito,Javier, AU - Simpson,Wendy, AU - Freire,Mila, AU - Lascelles,B Duncan X, Y1 - 2013/01/24/ PY - 2013/1/26/entrez PY - 2013/1/26/pubmed PY - 2014/2/15/medline SP - 678 EP - 90 JF - Journal of feline medicine and surgery JO - J. Feline Med. Surg. VL - 15 IS - 8 N2 - Medical records where tepoxalin (Zubrin) or meloxicam (Metacam) were prescribed in cats were reviewed and data extracted. Comparisons were performed for exploring changes between pre- and post-non-steroidal anti-inflammatory drug course laboratory tests. Seventy-nine medical records fit the inclusion criteria (n = 57 and n = 22, tepoxalin and meloxicam, respectively). The median dosages administered were 13 and 0.029 mg/kg(/)day (tepoxalin and meloxicam, respectively). Median prescription durations were 11 (2-919) and 93 (4-1814) days for tepoxalin and meloxicam, respectively. Suspected adverse events were reported for tepoxalin (9%, 5/57 cats) and meloxicam (18%, 4/22 cats) a median of 774 and 448 days, respectively, after the prescription started. For cats prescribed meloxicam, there were several statistically significant changes for serum biochemistry and hematology parameters, but median values were within normal limits. These valuable clinical data suggest that tepoxalin and meloxicam are well tolerated in the clinical setting at the doses prescribed in this study. SN - 1532-2750 UR - https://www.unboundmedicine.com/medline/citation/23349526/Evaluation_of_the_clinical_use_of_tepoxalin_and_meloxicam_in_cats_ L2 - http://journals.sagepub.com/doi/full/10.1177/1098612X12473994?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -